Roche Sees Biomarker Data As Support For Immuno-Oncology Strategy

Use of PD-L1 expression as a biomarker may be up for debate at ASCO, but Roche assures analysts that proper application will unlock its combination-heavy development strategy.

While the role of PD-L1 expression as a predictive biomarker continues to be a major focus of debate at the American Society of Clinical Oncology annual meeting, Roche is confident that the emerging data have vindicated its development strategy.

“Proof of concept has come with the POPLAR data” for the PD-L1 inhibitor atezolizumab (MPDL3280) in non-small cell lung cancer,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D